- Home
- PROF vs MCRB Comparison
PROF vs MCRB Comparison
Compare PROF & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- MCRB
- Stock Information
- Founded
- PROF N/A
- MCRB 2010
- Country
- PROF Canada
- MCRB United States
- Employees
- PROF N/A
- MCRB N/A
- Industry
- PROF Medical/Dental Instruments
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- PROF Health Care
- MCRB Health Care
- Exchange
- PROF Nasdaq
- MCRB Nasdaq
- Market Cap
- PROF 130.4M
- MCRB 144.6M
- IPO Year
- PROF N/A
- MCRB 2015
- Fundamental
- Price
- PROF $5.89
- MCRB $13.75
- Analyst Decision
- PROF Strong Buy
- MCRB Hold
- Analyst Count
- PROF 1
- MCRB 3
- Target Price
- PROF $11.00
- MCRB $14.33
- AVG Volume (30 Days)
- PROF 63.4K
- MCRB 93.1K
- Earning Date
- PROF 11-13-2025
- MCRB 11-05-2025
- Dividend Yield
- PROF N/A
- MCRB N/A
- EPS Growth
- PROF N/A
- MCRB N/A
- EPS
- PROF N/A
- MCRB 10.22
- Revenue
- PROF $11,840,000.00
- MCRB N/A
- Revenue This Year
- PROF $60.07
- MCRB N/A
- Revenue Next Year
- PROF $120.03
- MCRB N/A
- P/E Ratio
- PROF N/A
- MCRB $1.38
- Revenue Growth
- PROF 59.81
- MCRB N/A
- 52 Week Low
- PROF $3.76
- MCRB $6.53
- 52 Week High
- PROF $9.17
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- PROF 54.50
- MCRB 24.79
- Support Level
- PROF $5.65
- MCRB $15.51
- Resistance Level
- PROF $6.28
- MCRB $18.38
- Average True Range (ATR)
- PROF 0.35
- MCRB 1.19
- MACD
- PROF -0.01
- MCRB -0.50
- Stochastic Oscillator
- PROF 62.22
- MCRB 0.00
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.